Results 61 to 70 of about 13,466 (213)
Sclerostin: clinical insights in muscle–bone crosstalk
, 2023 Sclerostin, a protein encoded by the sclerostin (SOST) gene, is mostly expressed in osteocytes. First described in the pathogenesis of three disorders, sclerosteosis, van Buchem’s disease, and craniodiaphyseal dysplasia, sclerostin has been identified as
Moretti, Antimo +3 more
core +1 more source
Frontiers in Cell and Developmental Biology, 2020 Sclerostin is an important regulator of bone mass involving Wnt/β-catenin signaling pathway. We aimed to obtain the profile of serum sclerostin level and explore its associations with bone metabolism markers and sex hormones in healthy community-dwelling
Yang Xu +10 more
doaj +1 more source
BMEMat, EarlyView.This study reports a novel Zr58Cu25Al14Nb3 bulk metallic glass that possesses high mechanical strength and low elastic modulus, which further promotes efficient mechanotransduction and significantly improves peri‐implant bone quality upon cyclic occlusal loading.
Yunshu Wu +10 more
wiley +1 more source
iMeta, EarlyView.The Human Biomarker Navigator integrates the disease continuum, biomarker dynamics, cross‐organ biomarker networks, biomarker classification, and technology‐driven paradigms. It maps how biomarkers link multi‐system physiology and pathology across the nervous, respiratory, endocrine, circulatory, immune, digestive, urinary, reproductive, and ...
Meng‐Yao Li +29 more
wiley +1 more source
Kidney & Blood Pressure Research, 2015 Background/Aims: Cardiovascular calcification contributes to the increased mortality in hemodialysis patients. Sclerostin was identified as an antianabolic bone factor causing soft tissue calcification. Data on prospective large-scale studies associating
Albina Nowak +6 more
doaj +1 more source
Circulating levels of sclerostin are associated with cardiovascular mortality. [PDF]
PLoS ONE, 2018 Cardiovascular diseases are a health problem throughout the world, especially in people with diabetes. The identification of cardiovascular disease biomarkers can improve risk stratification.
Cristina Novo-Rodríguez +8 more
doaj +1 more source
Progress in bone tissue engineering biomaterials: Development, challenges, and prospects
VIEW, EarlyView.Scheme 1 Application of biomaterials in immunomodulation during bone tissue engineering. Abstract Bone defect repair remains a major clinical challenge in orthopedics. Over 2 million cases caused by trauma, tumors, and other factors occur annually, with large‐scale defects posing a particular bottleneck due to limited self‐healing capacity.
Yuanbin Zhang +7 more
wiley +1 more source
Anti-sclerostin antibody – A potential therapeutic target for periodontal bone regeneration
Journal of Oral Research and ReviewSclerostin is a glycoprotein predominantly released by specialized bone-forming cells (osteocytes). It serves as a principal inhibitor of osteogenesis and plays a key act in modulating the metabolism of alveolar bone. Sclerostin is shown to contribute to
Shruthi Reghunath +5 more
doaj +1 more source
The Effect of Renal Dysfunction on Circulating Sclerostin Level in Patients with Type 2 Diabetes
International Journal of Endocrinology, 2014 Objective. Sclerostin is a Wnt inhibitor produced specifically by osteocytes. However, it is not currently clear whether renal dysfunction has an effect on circulating sclerostin level in patients with type 2 diabetes.
Se Hwa Kim +3 more
doaj +1 more source
BMC Nephrology, 2019 Background Sclerostin, an antagonist of the Wingless-type mouse mammary tumor virus integration site (Wnt) pathway that regulates bone metabolism, is a potential contributor of chronic kidney disease (CKD)–mineral and bone disorder (MBD), which has ...
Te-Hui Kuo +7 more
doaj +1 more source